Incyte Q2 FY25: where the revenue came from and where it went
The whole income statement of Incyte for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Jul 29, 2025
Revenue$1.22B
+16% year over year
Gross profit$1.14B
94% margin
Operating profit$0.53B
44% margin
Net profit$0.41B
33% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.22 | 100% | +16% |
| Jakafi | 0.76 | 63% | |
| Opzelura | 0.16 | 13% | |
| Product royalty | 0.15 | 12% | |
| Niktimvo | 0.04 | 3% | |
| Iclusig | 0.03 | 3% | |
| Minjuvi/monjuvi | 0.03 | 3% | |
| Pemazyre | 0.02 | 2% | |
| Other | 0.01 | 1% | |
| Cost of revenue | −0.08 | 6% | |
| Gross profit | 1.14 | 94% margin | +1pp |
| R&D | −0.28 | 23% | −68pp |
| SG&A | −0.33 | 27% | −2pp |
| Operating profit | 0.53 | 44% margin | +89pp |
| Other income, net | 0.03 | ||
| Tax | −0.15 | ||
| Net profit | 0.41 | 33% margin | +76pp |
394 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest